AniCell new products benefit veterinarians and horse owners in EHV-1 outbreaks
At AniCell, we’re proud of the strides we’ve taken in veterinary care through our innovative technologies. Over the past few years, we’ve partnered with veterinarians and their clients, under USDA oversight, to explore the potential of our amnion-based technology in supporting equine health and welfare, as well as addressing economic concerns.
Together, we’ve gathered real-world evidence on the antimicrobial and bioscaffold properties of our technology, focusing on supporting the body’s natural immune defenses and facilitating self-healing, particularly against infectious diseases like EHV-1.
Under the guidance of Dr. Robert Holland, our studies have shown promising results, including positive impacts on raccoon parvovirus. Collaborations during the Fonner Park EHV-1 outbreak in 2022, supported by data from NVSL and UC Davis, further reinforced our findings.